Invesco Ltd. Has $28.85 Million Stock Position in Organon & Co. $OGN

Key Points

• Invesco Ltd. reduced its holdings in Organon & Co. by 4.8%, now owning approximately 1.94 million shares valued at about $28.85 million, accounting for 0.75% of the company's stock.
• Organon & Co. reported a net margin of 11.15% and a return on equity of 163.88% with quarterly earnings of $1.00 per share, surpassing analysts' estimates.
• The company announced a quarterly dividend of $0.02 per share, with a 0.9% yield and a payout ratio of 2.97%.

Invesco Ltd. trimmed its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,937,412 shares of the company's stock after selling 97,368 shares during the period. Invesco Ltd. owned about 0.75% of Organon & Co. worth $28,848,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Massachusetts Financial Services Co. MA lifted its holdings in shares of Organon & Co. by 8.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after purchasing an additional 820,378 shares during the last quarter. LSV Asset Management raised its position in Organon & Co. by 6.1% during the first quarter. LSV Asset Management now owns 7,980,775 shares of the company's stock valued at $118,834,000 after buying an additional 455,699 shares during the period. Deprince Race & Zollo Inc. raised its position in Organon & Co. by 7.0% during the fourth quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company's stock valued at $70,561,000 after buying an additional 308,267 shares during the period. Dimensional Fund Advisors LP raised its position in Organon & Co. by 23.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company's stock valued at $48,999,000 after buying an additional 629,191 shares during the period. Finally, Private Management Group Inc. raised its position in Organon & Co. by 1.1% during the first quarter. Private Management Group Inc. now owns 2,142,010 shares of the company's stock valued at $31,895,000 after buying an additional 22,722 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on OGN shares. Piper Sandler dropped their price target on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a research report on Friday, May 2nd. Morgan Stanley dropped their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Finally, BNP Paribas raised Organon & Co. to a "strong-buy" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $18.00.

Organon & Co. Stock Up 1.5%

Shares of NYSE OGN traded up $0.14 during mid-day trading on Friday, reaching $9.42. 3,550,502 shares of the company traded hands, compared to its average volume of 4,782,985. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market cap of $2.45 billion, a PE ratio of 3.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.60. The company's fifty day moving average is $9.68 and its two-hundred day moving average is $11.45. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm's revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. On average, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.8%. Organon & Co.'s dividend payout ratio (DPR) is 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.